{
  "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
  "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 60,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/41",
  "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
  "deckJsonHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9.json",
  "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.11,
        "x": 0.87,
        "y": 0.05
      },
      "kind": "image",
      "text": "IMMIX BIOPHARMA",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "955d8605-3fd2-4c61-bb64-ad1759c6b685",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.59,
        "x": 0.02,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: Berdeja JG, et al. Lancet. 2021; Frigault MJ, et al. Blood Adv. 2023; Munshi NC, et al. N Engl J Med. 2021; Asherie N, et al. Haematologica. 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fd6b570-6dde-41cb-a1d5-1626b06032be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.96,
        "x": 0.02,
        "y": 0.317
      },
      "kind": "table",
      "text": "Comparison of NXC-201, Abecma, Carvykti, and CART-ddBCMA across regimen, frequency, and infusion timing.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6b9423d-7d51-4a00-8209-35390446878d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.27,
        "x": 0.02,
        "y": 0.06
      },
      "kind": "title",
      "text": "Preconditioning Regimens",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96d675c6-3944-4014-9739-04ada58913a4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 60,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
      "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
      "position": 1,
      "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}